Type IV hyperlipoproteinaemia

Peter O. Kwiterovich, Simeon Margolis

Research output: Contribution to journalArticle

Abstract

Endogenous hyperglyceridaemia, or type IV hyperlipoproteinaemia is the most common variety of triglyceride elevation. The minimal requirements to make the chemical diagnosis of type IV H.L.P. include sampling blood under standardised conditions, observation of standing plasma, and measurement of plasma cholesterol and triglycerides. Elimination of the many phenocopies of type IV H.L.P. is necessary before a diagnosis of primary type IV H.L.P. can be made. Family screening is currently required to document the familial nature of this disorder, because no qualitative markers of the type IV H.L.P. are presently available. Although familial type IV H.L.P. is undoubtedly heterogeneous, it behaves in some families as a Mendelian dominant trait with delayed penetrance. The clinical manifestations of type IV H.L.P. vary in different patients but include premature vascular disease of the coronary and peripheral vessels, xanthomas, and acute pancreatitis. Glucose intolerance, diabetes and hyperuricaemia are other common findings in these patients. The metabolism of VLDL is complex and involves the interrelationships of lipid, carbohydrate and lipoprotein metabolism. Possible biochemical defects in type IV H.L.P. may involve the synthesis, secretion or catabolism of VLDL. The presence of carbohydrate intolerance may be a clue to the defects in type IV H.L.P. The possible role of insulin in the pathogenesis of the disorder(s) is unsettled; peripheral resistance to insulin, insulin deficiency and hyperinsulinism have all been implicated in type IV H.L.P. Treatment of the hyperglyceridaemia in the patient with type IV H.L.P. is indicated for two reasons: first, to relieve or avoid the complications of severe hyperglyceridaemia, e.g. eruptive xanthomas or pancreatitis; and, secondly, hopefully to prevent or regress premature coronary and peripheral vascular disease. Epidemiological and family studies have demonstrated a relationship between elevated plasma triglyceride levels and the risk of coronary heart disease. Although it has not been proven that lowering cholesterol or triglyceride levels will alter the atherosclerotic process, treatment appears judicious at this point. The cornerstone of therapy for type IV H.L.P. is diet. Drug therapy is indicated in some patients and either clofibrate (Atromid-S) or nicotinic acid has been used with some success.

Original languageEnglish (US)
Pages (from-to)41-71
Number of pages31
JournalClinics in Endocrinology and Metabolism
Volume2
Issue number1
DOIs
StatePublished - 1973
Externally publishedYes

Fingerprint

Hyperlipoproteinemia Type IV
Triglycerides
Xanthomatosis
Clofibrate
Peripheral Vascular Diseases
Insulin
Plasmas
Metabolism
Pancreatitis
Cholesterol
Carbohydrates
Drug therapy
Defects
Glucose Intolerance
Penetrance
Niacin
Carbohydrate Metabolism
Hyperinsulinism
Nutrition
Medical problems

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Type IV hyperlipoproteinaemia. / Kwiterovich, Peter O.; Margolis, Simeon.

In: Clinics in Endocrinology and Metabolism, Vol. 2, No. 1, 1973, p. 41-71.

Research output: Contribution to journalArticle

Kwiterovich, Peter O. ; Margolis, Simeon. / Type IV hyperlipoproteinaemia. In: Clinics in Endocrinology and Metabolism. 1973 ; Vol. 2, No. 1. pp. 41-71.
@article{93697dd256084c4d8b324ebb2c8852ac,
title = "Type IV hyperlipoproteinaemia",
abstract = "Endogenous hyperglyceridaemia, or type IV hyperlipoproteinaemia is the most common variety of triglyceride elevation. The minimal requirements to make the chemical diagnosis of type IV H.L.P. include sampling blood under standardised conditions, observation of standing plasma, and measurement of plasma cholesterol and triglycerides. Elimination of the many phenocopies of type IV H.L.P. is necessary before a diagnosis of primary type IV H.L.P. can be made. Family screening is currently required to document the familial nature of this disorder, because no qualitative markers of the type IV H.L.P. are presently available. Although familial type IV H.L.P. is undoubtedly heterogeneous, it behaves in some families as a Mendelian dominant trait with delayed penetrance. The clinical manifestations of type IV H.L.P. vary in different patients but include premature vascular disease of the coronary and peripheral vessels, xanthomas, and acute pancreatitis. Glucose intolerance, diabetes and hyperuricaemia are other common findings in these patients. The metabolism of VLDL is complex and involves the interrelationships of lipid, carbohydrate and lipoprotein metabolism. Possible biochemical defects in type IV H.L.P. may involve the synthesis, secretion or catabolism of VLDL. The presence of carbohydrate intolerance may be a clue to the defects in type IV H.L.P. The possible role of insulin in the pathogenesis of the disorder(s) is unsettled; peripheral resistance to insulin, insulin deficiency and hyperinsulinism have all been implicated in type IV H.L.P. Treatment of the hyperglyceridaemia in the patient with type IV H.L.P. is indicated for two reasons: first, to relieve or avoid the complications of severe hyperglyceridaemia, e.g. eruptive xanthomas or pancreatitis; and, secondly, hopefully to prevent or regress premature coronary and peripheral vascular disease. Epidemiological and family studies have demonstrated a relationship between elevated plasma triglyceride levels and the risk of coronary heart disease. Although it has not been proven that lowering cholesterol or triglyceride levels will alter the atherosclerotic process, treatment appears judicious at this point. The cornerstone of therapy for type IV H.L.P. is diet. Drug therapy is indicated in some patients and either clofibrate (Atromid-S) or nicotinic acid has been used with some success.",
author = "Kwiterovich, {Peter O.} and Simeon Margolis",
year = "1973",
doi = "10.1016/S0300-595X(73)80026-X",
language = "English (US)",
volume = "2",
pages = "41--71",
journal = "Clinics in Endocrinology and Metabolism",
issn = "0300-595X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Type IV hyperlipoproteinaemia

AU - Kwiterovich, Peter O.

AU - Margolis, Simeon

PY - 1973

Y1 - 1973

N2 - Endogenous hyperglyceridaemia, or type IV hyperlipoproteinaemia is the most common variety of triglyceride elevation. The minimal requirements to make the chemical diagnosis of type IV H.L.P. include sampling blood under standardised conditions, observation of standing plasma, and measurement of plasma cholesterol and triglycerides. Elimination of the many phenocopies of type IV H.L.P. is necessary before a diagnosis of primary type IV H.L.P. can be made. Family screening is currently required to document the familial nature of this disorder, because no qualitative markers of the type IV H.L.P. are presently available. Although familial type IV H.L.P. is undoubtedly heterogeneous, it behaves in some families as a Mendelian dominant trait with delayed penetrance. The clinical manifestations of type IV H.L.P. vary in different patients but include premature vascular disease of the coronary and peripheral vessels, xanthomas, and acute pancreatitis. Glucose intolerance, diabetes and hyperuricaemia are other common findings in these patients. The metabolism of VLDL is complex and involves the interrelationships of lipid, carbohydrate and lipoprotein metabolism. Possible biochemical defects in type IV H.L.P. may involve the synthesis, secretion or catabolism of VLDL. The presence of carbohydrate intolerance may be a clue to the defects in type IV H.L.P. The possible role of insulin in the pathogenesis of the disorder(s) is unsettled; peripheral resistance to insulin, insulin deficiency and hyperinsulinism have all been implicated in type IV H.L.P. Treatment of the hyperglyceridaemia in the patient with type IV H.L.P. is indicated for two reasons: first, to relieve or avoid the complications of severe hyperglyceridaemia, e.g. eruptive xanthomas or pancreatitis; and, secondly, hopefully to prevent or regress premature coronary and peripheral vascular disease. Epidemiological and family studies have demonstrated a relationship between elevated plasma triglyceride levels and the risk of coronary heart disease. Although it has not been proven that lowering cholesterol or triglyceride levels will alter the atherosclerotic process, treatment appears judicious at this point. The cornerstone of therapy for type IV H.L.P. is diet. Drug therapy is indicated in some patients and either clofibrate (Atromid-S) or nicotinic acid has been used with some success.

AB - Endogenous hyperglyceridaemia, or type IV hyperlipoproteinaemia is the most common variety of triglyceride elevation. The minimal requirements to make the chemical diagnosis of type IV H.L.P. include sampling blood under standardised conditions, observation of standing plasma, and measurement of plasma cholesterol and triglycerides. Elimination of the many phenocopies of type IV H.L.P. is necessary before a diagnosis of primary type IV H.L.P. can be made. Family screening is currently required to document the familial nature of this disorder, because no qualitative markers of the type IV H.L.P. are presently available. Although familial type IV H.L.P. is undoubtedly heterogeneous, it behaves in some families as a Mendelian dominant trait with delayed penetrance. The clinical manifestations of type IV H.L.P. vary in different patients but include premature vascular disease of the coronary and peripheral vessels, xanthomas, and acute pancreatitis. Glucose intolerance, diabetes and hyperuricaemia are other common findings in these patients. The metabolism of VLDL is complex and involves the interrelationships of lipid, carbohydrate and lipoprotein metabolism. Possible biochemical defects in type IV H.L.P. may involve the synthesis, secretion or catabolism of VLDL. The presence of carbohydrate intolerance may be a clue to the defects in type IV H.L.P. The possible role of insulin in the pathogenesis of the disorder(s) is unsettled; peripheral resistance to insulin, insulin deficiency and hyperinsulinism have all been implicated in type IV H.L.P. Treatment of the hyperglyceridaemia in the patient with type IV H.L.P. is indicated for two reasons: first, to relieve or avoid the complications of severe hyperglyceridaemia, e.g. eruptive xanthomas or pancreatitis; and, secondly, hopefully to prevent or regress premature coronary and peripheral vascular disease. Epidemiological and family studies have demonstrated a relationship between elevated plasma triglyceride levels and the risk of coronary heart disease. Although it has not been proven that lowering cholesterol or triglyceride levels will alter the atherosclerotic process, treatment appears judicious at this point. The cornerstone of therapy for type IV H.L.P. is diet. Drug therapy is indicated in some patients and either clofibrate (Atromid-S) or nicotinic acid has been used with some success.

UR - http://www.scopus.com/inward/record.url?scp=0015599421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015599421&partnerID=8YFLogxK

U2 - 10.1016/S0300-595X(73)80026-X

DO - 10.1016/S0300-595X(73)80026-X

M3 - Article

VL - 2

SP - 41

EP - 71

JO - Clinics in Endocrinology and Metabolism

JF - Clinics in Endocrinology and Metabolism

SN - 0300-595X

IS - 1

ER -